(Q47335455)

14 January 2018

title

Incidence of invasive pneumococcal disease before and during an era of use of three different pneumococcal conjugate vaccines in Quebec (English)

1 reference

14 January 2018

3

Geneviève Deceuninck

1 reference

14 January 2018

author name string

Philippe De Wals

series ordinal

1

1 reference

14 January 2018

Brigitte Lefebvre

series ordinal

2

1 reference

14 January 2018

Jean Longtin

series ordinal

4

1 reference

14 January 2018

language of work or name

English

0 references

publication date

7 December 2017

1 reference

14 January 2018

published in

Vaccine

1 reference

14 January 2018

volume

36

1 reference

14 January 2018

issue

3

1 reference

14 January 2018

page(s)

421-426

1 reference

14 January 2018

Impact of 2+1 pneumococcal conjugate vaccine program in the province of Quebec, Canada

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.11.054

Uptake of pneumococcal conjugate vaccine: methodological issues in measurement and impact of publicly funded programs.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.11.054

Serotype distribution of invasive Streptococcus pneumoniae in Canada after the introduction of the 13-valent pneumococcal conjugate vaccine, 2010–2012

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.11.054

Interim results of an ecological experiment - Conjugate vaccination against the pneumococcus and serotype replacement

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.11.054

Serotype-specific changes in invasive pneumococcal disease after pneumococcal conjugate vaccine introduction: a pooled analysis of multiple surveillance sites

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.11.054

Effectiveness of ten-valent pneumococcal conjugate vaccine against invasive pneumococcal disease in Brazil: a matched case-control study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.11.054

Indirect cohort analysis of 10-valent pneumococcal conjugate vaccine effectiveness against vaccine-type and vaccine-related invasive pneumococcal disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.11.054

Effectiveness of three pneumococcal conjugate vaccines to prevent invasive pneumococcal disease in Quebec, Canada

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.11.054

Immune response to 13-valent pneumococcal conjugate vaccine with a reduced dosing schedule

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.11.054

Serotype-specific effectiveness and correlates of protection for the 13-valent pneumococcal conjugate vaccine: a postlicensure indirect cohort study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.11.054

Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.11.054

Effectiveness of Pneumococcal Conjugate Vaccines (PCV7 and PCV13) against Invasive Pneumococcal Disease among Children under Two Years of Age in Germany

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.11.054

Vaccine effectiveness of PCV13 in a 3+1 vaccination schedule

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.11.054

10.1016/J.VACCINE.2017.11.054

7 January 2021

Identifiers

DOI

1 reference

14 January 2018

1 reference

14 January 2018